에 대한 최신 뉴스 QuantumScape (NYSE:QS) 주식

QUANTUMSCAPE CORP

QuantumScape

QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.

Binary,Options,Chart

Equities

News

Markets

$BTC

BBAI

COIN

TSLA

화요일 미국 주식 시장은 이날 상승세로 마감했다. 나스닥은 화요일에 1.4% 상승하여 19,912.53포인트에 도달했다. 다우도 1.2% 상승하여 43,089.02포인트에 거래되었으며, S&amp;P 500은 1.1% 상승하여 6,092.18포인트로 올랐다.
다음은 하루 동안 소매 투자자와 트레이더들의 주목을 받은 주요 주식이다.
빅베어AI (NYSE:BBAI)

화요일 주목받은 주식: 빅베어AI, AMD, 퀀텀스케이프, 코인베이스 및 테슬라

Mid Cap

Short Ideas

Options

Trading Ideas

전 세계적으로 전기차(EV) 산업이 급성장함에 따라, 이는 전기차 배터리 기술 전문 기업인 퀀텀스케이프(NYSE:QS)에 두 가지 이점을 제공한다. 첫째, 분명한 점은 차세대 차량이 많아지면 고급 배터리에 대한 수요가 높아진다는 것이다. 둘째, 에너지 효율적인 발전소는 전력망 인프라에 가해지는 추가 부담을 완화하는 데 도움이 될 것이다. 따라서 QS 주식이 가끔 큰 폭으로 상승하는 것은 놀라운 일이 아니다.

옵션 코너: 퀀텀스케이프 랠리가 무력해질 때 방어 전략 사용하기

QuantumScape QS Stock

Earnings

After-Hours Center

Movers

퀀텀스케이프(NYSE:QS)는 수요일 2분기 재무 결과를 발표했다. 세부사항은 다음과 같다. 주요 내용: 퀀텀스케이프는 GAAP 분기별 손실을 주당 25센트로 보고했는데, 이는 분석가의 합의 손실 추정치인 23센트를 8.7%나 하회한 것이다.

퀀텀스케이프의 주식은 부진한 2분기 실적으로 시간외 거래에서 하락

QuantumScape Corporation Class A Common Stock

QuantumScape Corp

QSAM Biosciences Inc

Q.Beyond AG

Quartzsea Acquisition Corporation - Ordinary Shares

Quartzsea Acquisition Corp

Quartzsea Acquisition Corporation - Rights

Quartzsea Acquisition Corporation - Units

QS Energy Inc

QuantaSing Group Limited - American Depositary Shares

QuantaSing Group Ltd

INSTITUTE FOR Q SHU PIONR by INSTITUTE FOR Q SHU PIONEERS OF SPACE INC.

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si Inc

WisdomTree U.S. Short Term Corporate Bond Fund

Pacer Metaurus Nasdaq 100 Dividend Multiplier 600 ETF

TANCHENG GROUP CO LTD by Tancheng Group Co., Ltd.

Tancheng Group Co Ltd

WisdomTree U.S. SmallCap Quality Growth Fund

Quantstamp - United States Dollar

FT Vest Nasdaq-100 Buffer ETF - September

QUANTUM SOLAR POWER CORP by Quantum Solar Power Corp.

Quantum Solar Power Corp

Restaurant Brands International Inc. Common Shares

Restaurant Brands International Inc

Amplify ETF Trust BlackSwan Tech & Treasury ETF

Contineum Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and progressive multiple sclerosis (PrMS) cohorts of this trial. The screening and enrollment of idiopathic pulmonary fibrosis (IPF) patients to participate in this trial is ongoing.

Biotech

General

CNTM

CTNM

Contineum Therapeutics Completes PrMS And Healthy Volunteer Enrollment In Phase 1b PET Trial Of PIPE-791

Stryker Announces FDA Clearance For Its Incompass Total Ankle System

Novagold Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NG#AMEX">NG</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is unchanged from the same period last year.

Earnings Misses

Novagold Resources Q2 Adj. EPS $(0.04) Misses $(0.03) Estimate

SeaStar Medical Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that it has undertaken a series of transactions to ensure compliance with Nasdaq's continued listing standards.&nbsp;&nbsp;
Last year on June 24, 2024, SeaStar Medical received a written notification from Nasdaq's Listing Qualifications Staff that it was not in compliance with the requirement to maintain a minimum market value of listed securities of $35 million as required by Nasdaq Listing Rule 5550(b)(2). After a hearing before the Nasdaq Hearings Panel (the "Panel"), the Panel granted the Company an extension through June 22, 2025, to evidence compliance with the alternative requirement of $2.5 million in stockholders' equity.
SeaStar Medical has completed the following capital transactions and operational improvements to evidence compliance with the Nasdaq equity rule:
Fundraising transactions:
<ul>
<li>On June 23, 2025, SeaStar Medical completed a $4.0 million public offering of common stock and warrants.</li>
<li>On April 25, 2025, SeaStar Medical entered into a purchase agreement with Lincoln Park Capital, pursuant to which Lincoln Park agreed to purchase up to an aggregate of $15.0 million of our common stock from time to time over a three-year term.</li>
</ul>
Revenue generation:
<ul>
<li>In the second fiscal quarter, SeaStar Medical continued to advance its business plan by increasing its customer count to six for the Company's FDA approved product, QUELIMMUNE, which is used by ICU physicians treating pediatric patients with multiple organ failure. QUELIMMUNE has been shown to reduce pediatric mortality by approximately 50% and completely relieve pediatric patients from a lifetime of dialysis. &nbsp;</li>
</ul>
Operating expense reduction:
<ul>
<li>In May 2025, SeaStar Medical began a cost cutting program that is expected to reduce operating expenses for the remainder of the current fiscal year. The Company does not anticipate that these expense reductions will have a material impact on operations. &nbsp;</li>
</ul>
Liability restructuring:
<ul>
<li>In May and June of 2025, approximately $1.2 million of employee compensation and director fee liabilities were extinguished as certain employees and directors waived their rights to bonuses and fees that had accrued but not paid. &nbsp;</li>
</ul>
Based on the above, SeaStar Medical believes it has regained compliance with the $2.5 million stockholders' equity requirement for continued listing on The Nasdaq Capital Market.&nbsp;&nbsp; However, the Company awaits Nasdaq's formal confirmation of compliance.

SeaStar Medical Undertakes Strategic Transactions Including Fundraising Transactions, Revenue Generation, Operating Expense Reduction And Liability Restructuring, To Regain Nasdaq Compliance, Awaits Confirmation

We Energies  To Extend Operating Lives Of Units 7 And 8 At Oak Creek Power Plant Through End Of 2026, Postponing Retirement Date From End Of 2025

<ul>
<li>Initial computational analysis demonstrated that Evaxion's AI-Immunology&#x2122; platform can identify novel vaccine targets to combat Group A Streptococcus (GAS)</li>
<li>New vaccine program is added to Evaxion's pipeline under the name EVX-B4</li>
<li>Urgent need for preventive measures against GAS underscores the significant medical and commercial potential of EVX-B4</li>
<li>Addition of a novel infectious disease candidate to the pipeline is in line with Evaxion's partnership strategy</li>
</ul>
COPENHAGEN, Denmark, June 25, 2025 - Evaxion A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology&#x2122; powered vaccines, initiates work to develop a new preventive vaccine against Group A Streptococcus (GAS), a bacteria causing hundreds of millions of infections globally each year. Infection carries the risk of several complications including life threatening conditions like rheumatic heart disease and necrotizing fasciitis ("flesh eating bacteria") and less severe yet serious diseases like strep throat and scarlet fever.
The new vaccine program, named EVX-B4, has been added to Evaxion's research &amp; development (R&amp;D) pipeline of cancer and infectious disease vaccine candidates. Initial computational analysis demonstrated that AI-Immunology&#x2122; can identify novel vaccine targets to combat GAS, which could pave the way for a new approach to fight the bacteria. Deploying AI-Immunology&#x2122; allows for fast and effective target discovery, design and validation, accelerating preclinical development of EVX-B4. This work will create a comprehensive preclinical data package to facilitate partnership discussions.
Adding EVX-B4 to the pipeline achieves another of Evaxion's milestones for 2025. Evaxion's R&amp;D pipeline now comprises five specified vaccine candidates for infectious diseases and three for cancer. The build-up of the pipeline supports Evaxion's partnership strategy as we increase the number of assets for out-licensing.

EVAX

Evaxion Initiates Work To Develop New Preventive Vaccine Against Group A Streptococcus; New Vaccine Program Added To Evaxion's Pipeline Under Name EVX-B4

Raymond James Ltd enters into agreement with FNZ to accelerate its digital transformation
&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4456311-1&amp;h=3952077249&amp;u=https%3A%2F%2Fwww.raymondjames.ca%2F&amp;a=Raymond+James+Ltd.">Raymond James Ltd.</a>, the largest independent financial services firm in Canada, today announced a strategic partnership with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4456311-1&amp;h=2547701680&amp;u=https%3A%2F%2Fwww.fnz.com%2F&amp;a=FNZ">FNZ</a>, a global wealth management platform provider, to deliver its next-generation wealth management platform. Under the agreement, Raymond James Ltd. will make a significant investment to accelerate the digital transformation of its wealth management infrastructure and elevate the advisor and client experience nationwide.
The partnership will see Raymond James Ltd. leverage FNZ's integrated, end-to-end wealth management platform—a deliberate and future-focused investment in modern infrastructure. Designed to deliver AI-powered capabilities, straight-through processing, and advanced digital capabilities, the FNZ platform will strengthen the Raymond James Ltd. unique value proposition.
"As a client-first organization, we took the time to engage with our advisors, branch associates and clients to define the future of wealth management," said Jamie Coulter CEO, Raymond James Ltd. "This isn't just a technology upgrade—it's a quantum leap in the support we provide our advisors in their delivery of exceptional client service. We're listening, investing, and acting to deliver smarter, more connected experiences for our partners and clients."
The new platform is built with a client-centric, digital-first design that improves efficiency, speed and personalization across the full wealth lifecycle. Advisors will gain a modern, intuitive operating environment, enabling more meaningful client engagements. Investors will benefit from improved digital experiences and real-time capabilities, all backed by the highest level of security and performance provided by the FNZ platform.
This strategic investment strengthens Raymond James Ltd.'s position as a premier destination for top-tier advisors across Canada, reinforcing its commitment to innovation, advisor enablement, and exceptional client service.
FNZ partners with more than 650 financial institutions globally on behalf of 26 million end investors and administers with more than US$ 1.7 trillion in assets. FNZ's market-leading technology and infrastructure will significantly enhance Raymond James Ltd.'s offering to advisors with greater flexibility to adapt quickly to changing markets, regulatory requirements, and investor expectations.
Blythe Masters, Group CEO of FNZ, said: "We are delighted to partner with Raymond James Ltd. to deliver a next-generation wealth management platform that will transform the advisor and client experience across Canada. North America is a key market for FNZ, and this partnership reflects our long-term commitment to investing in the region.
We're excited to bring this innovative platform to life and support Raymond James Ltd. in setting a new standard for wealth management in Canada."
Positioning itself as a leader in financial technology and innovation, Raymond James expects to invest approximately US$1 billion globally in FY2025, with a strong emphasis on information security infrastructure including its dedicated Cyber Threat Center.

Contracts

Raymond James Enters Strategic Partnership With FNZ To Deliver Its Next-generation Wealth Management Platform

Stock Split

TRNR

Interactive Strength shares are trading lower after the company announced a 1-for-10 reverse stock split.

Interactive Strength To Conduct 1-for-10 Reverse Split

SLNO

Soleno Therapeutics Highlights New Data On VYKATTM XR Extended-Release Tablets, Previously Known As DCCR, At 2025 United In Hope: International Prader-Willi Syndrome Conference

Goldman Sachs analyst Leah Jordan upgrades Kraft Heinz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) from Sell to Neutral and raises the price target from $25 to $27.

Upgrades

Price Target

Analyst Ratings

Goldman Sachs Upgrades Kraft Heinz to Neutral, Raises Price Target to $27

Regenerative Medicine Advanced Therapy (RMAT) designation provides access to accelerated development tools
Designation recognizes the potential of detalimogene to address significant unmet need
enGene Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>, or "enGene" or the "Company"))), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also known as detalimogene, and previously EG-70), the Company's lead investigational therapy for the treatment of high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
The RMAT program is intended to expedite the development and review of regenerative medicine therapies for serious or life-threatening conditions, where preliminary clinical evidence suggests potential to address unmet medical needs. This designation provides enGene with several regulatory advantages, including early and frequent engagement with the FDA, potential for rolling review and priority review, and other benefits like Fast Track and Breakthrough Therapy designations.
"Receiving the RMAT designation highlights the promising profile of detalimogene and its potential to address the high unmet need in NMIBC," stated Ron Cooper, Chief Executive Officer of enGene. "Bladder cancer patients with limited options cannot wait, and we are enthusiastic about potentially expediting the regulatory process to bring a first-in-class treatment to patients."
The designation was based on previously disclosed preliminary results from the ongoing pivotal LEGEND study, which demonstrated compelling clinical activity and a generally favorable tolerability profile in patients with BCG-unresponsive NMIBC with CIS.
Detalimogene is designed for streamlined administration in urology clinics — including community practices, where approximately 70% of urologists provide care. The therapy is being evaluated for its ability to treat NMIBC though the non-viral stimulation of a local immune response in the bladder, presenting a potentially transformative option for patients who otherwise face limited choices beyond radical cystectomy.
About Non-Muscle Invasive Bladder Cancer (NMIBC) Non-muscle invasive bladder cancer (NMIBC) is a disease that poses a significant burden on both patients and clinics and has a massive economic impact on our healthcare system. NMIBC occurs when cancer cells grow in the tissues that line the interior of the bladder, but the cancer has not yet penetrated the muscle of the bladder wall. NMIBC can take the form of papillary outgrowths from the bladder wall, which are typically resected, or carcinoma in situ (CIS), flat, multifocal lesions that are unable to be resected, and the two can co-occur. About 75-80% of new bladder cancer diagnoses are NMIBC. Patients suffering from high-risk NMIBC who are unresponsive to the standard of care, Bacillus Calmette-Guérin (BCG), face high rates of disease recurrence (50-70%) and are subject to full removal of the bladder (cystectomy) as a curative but life-altering next step.

ENGN

enGene Holdings Announces The U.S. FDA Has Granted Regenerative Medicine Advanced Therapy Designation To Detalimogene Voraplasmid For Expedited Review In High-Risk, Non-Muscle Invasive Bladder Cancer

Fangdd Network Group Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement

New eBee X units enhance capabilities across agriculture, urban planning, and strategic applications
WICHITA, Kan., June 25, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NYSE">UAVS</a>), a leading provider of advanced drone and aerial imaging solutions, announces the sale of two additional eBee X drones to South Korea, expanding the country's installed base of AgEagle's eBee drones to more than 100 units. This milestone strengthens AgEagle's strategic partnership with South Korea and reinforces its position as a leader in the Asia-Pacific drone market.
The eBee X, AgEagle's flagship fixed-wing mapping drone, is engineered for high-precision geospatial data collection and is ideally suited for applications including surveying, mapping, and photogrammetry. This latest sale builds on a well-established fleet, further strengthening AgEagle's reputation as a trusted provider of cutting-edge unmanned aerial systems.

UAVS

AgEagle Expands South Korea Partnership With New eBee X Drone Sales, Surpassing 100 Units

OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) and Entera Bio Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTX#NASDAQ">ENTX</a>) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA.
Oral OPK-88006 is being developed pursuant to a collaboration and license agreement between OPKO and Entera whereby the companies are advancing a proprietary novel dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment and as a weekly subcutaneous injection for patients with obesity, metabolic and fibrotic disorders. The oral program combines OPKO's proprietary long-acting oxyntomodulin analog (OPK-88006) and Entera's proprietary N-Tab&#x2122; technology.

ENTX

OPKO Health And Entera Bio Say New Pharmacologic And Pharmacokinetic In Vivo Data For Investigational Oral OPK-88006 Tablet Treatment Selected For Presentation At ENDO 2025 Annual Meeting

Management

ICCC

ImmuCell Commences Search For President And CEO Successor

Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) has <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46090338/nextracker-selected-for-landmark-european-solar-power-project" rel="noreferrer noopener">expanded its global clean energy presence</a> by supplying its NX Horizon solar tracking systems to Greece&#8217;s largest solar installation, the 550 MW Oricheio PPC Ptolemaida Solar PV Park in Western Macedonia.
Led by PPC Renewables, a subsidiary of Greece&#8217;s state-owned PPC Group, the project repurposes a former coal mine into a clean energy hub. Once operational, the solar park is expected to generate nearly 1.8% of the country&#8217;s annual electricity supply.
Engineering firm Terna SA oversaw construction, implementing Nextracker&#8217;s technology to support Greece&#8217;s shift toward renewable energy. The project aligns with Greece&#8217;s revised National Energy and Climate Plan, which now aims for 82% of electricity generation from renewable sources by 2030, up from a previous goal of 66%.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/mid-cap/25/05/45613306/nextracker-bolsters-india-presence-with-10-gw-milestone-new-hyderabad-hub" rel="noreferrer noopener">Nextracker Bolsters India Presence With 10 GW Milestone, New Hyderabad Hub</a>
Nextracker President Howard Wenger called the project &#8220;an important step to increase energy independence in Europe and derisk capacity shortages for the region&#8221; and commended PPC and Terna for their high execution standards.
According to Wood Mackenzie, Nextracker leads the solar tracker market in Europe and globally, with more than 130 gigawatts of systems shipped. To meet rising demand, the company has expanded its local manufacturing partnerships across Europe, ensuring timely delivery and support for large-scale and distributed-generation projects.
Investors can also gain exposure to the solar sector via ETFs like Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) and iShares Global Clean Energy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLN#NASDAQ">ICLN</a>).
Price Action: NXT shares were trading lower by 0.017% to $57.25 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46089609/trump-administration-ordered-to-release-billions-in-ev-charger-funds-after-federal-judge-ruling" target="_blank" rel="noreferrer noopener">Trump Administration Ordered To Release Billions In EV Charger Funds After Federal Judge Ruling</a></li>
</ul>
Photo by fuyu liu via Shutterstock

Large Cap

iShares S&P Global Clean Energy Index Fund

ICLN

Nextracker's Tech Powers Greece's Largest Solar Park

VERI

Veritone Awarded Sole Source Contract With Air Force Office of Special Investigations, Terms Not Disclosed

Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in&nbsp;China,&nbsp;Angel Pharmaceuticals Ltd.&nbsp;(Angel Pharma), has been approved by the&nbsp;Center for Drug Evaluation&nbsp;(CDE) of the&nbsp;China National Medical Products Administration&nbsp;(NMPA) to initiate a Phase 1b/2 clinical trial of soquelitinib for the treatment of patients with moderate-to-severe atopic dermatitis in&nbsp;China.
Corvus co-founded Angel Pharma to develop its pipeline in greater&nbsp;China.&nbsp;Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize soquelitinib in greater&nbsp;China and is responsible for all expenses related to its development in&nbsp;China.
Angel Pharma's Phase 1b/2 clinical trial for soquelitinib in patients with atopic dermatitis will build on the data previously presented by Corvus from its ongoing Phase 1 trial by studying a longer treatment period and an additional dosing option. The Phase 1b trial will be randomized, double-blinded, placebo-controlled and enroll patients with moderate-to-severe atopic dermatitis as follows:
<ul>
<li>Soquelitinib Cohort 1 (24 patients) – 8 patients receive placebo, 8 patients receive soquelitinib 100 mg twice per day and 8 patients receive soquelitinib 200 mg once per day</li>
<li>Soquelitinib Cohort 2 (24 patients) – 8 patients receive placebo, 8 patients receive soquelitinib 200 mg twice per day and 8 patients receive soquelitinib 400 mg once per day</li>
<li>The treatment period will be 12 weeks</li>
</ul>
The Phase 2 trial will also be a randomized, double-blinded, placebo-controlled study. It will enroll additional patients and focus on two doses that will be selected based on the safety and efficacy results from the Phase 1b trial.
The principal investigator of the Phase 1b/2 clinical trial is Yuling Shi, M.D, Ph.D. Dr. Shi is professor of dermatology, the Vice President of Shanghai Skin Disease Hospital at the Tongji University School of Medicine, and the founder and director of the Institute of Psoriasis at Tongji University School of Medicine, the first psoriasis institute in China. Dr. Shi has published more than 100 peer-reviewed articles, most focusing on psoriasis, skin autoimmunity, and inflammatory skin diseases.

CRVS

Corvus Says Partner Angel Pharma's IND Approved By CDE Of China NMPA To Initiate Phase 1b/2 Clinical Trial Of Soquelitinib For Treatment Atopic Dermatitis In China

WIIM

FedEx shares are trading lower following soft Q1 guidance.

Press Releases

QuantumScape Reports Third Quarter 2024 Business and Financial Results

QuantumScape Releases Next-Generation Solid-State Battery Separator Equipment, Cobra

QuantumScape Announces Timing of Fourth Quarter 2024 Business Results and Webcast

QuantumScape Reports Fourth Quarter 2024 Business and Financial Results

Tech That Will Change Your Life in 2025

QuantumScape Announces Timing of First Quarter 2025 Business Results and Webcast

QuantumScape Reports First Quarter 2025 Business and Financial Results

QuantumScape and Murata Announce Framework for Ceramics Collaboration

Global Energy Investments To Hit Record $3.3 Trillion This Year: Report

QuantumScape Achieves Major Milestone: Cobra Separator Process Enters Baseline Production

FSLR

GOOG

MSFT

NVDA

SHEL

Adient

Autoliv

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Hldgs

BorgWarner

Cooper-Standard Holdings Inc. Common Stock

Cooper-Standard Holdings

Dana

Dorman Products

ECARX Holdings Inc. - Class A Ordinary shares

ECARX Holdings

Fox Factory Holding

Gentex

Garrett Motion

Holley

Hesai Group - American Depositary Share, each ADS represents one Class B ordinary share

Hesai Gr

LCI Industries

Lear

Mobileye Global Inc. - Class A Common Stock

Mobileye Global

Modine Manufacturing Company Common Stock

Modine Manufacturing

Patrick Industries

Phinia

Solid Power

Standard Motor Products, Inc. Common Stock

Standard Motor Products

Gentherm

Visteon

WeRide

XPEL

Goldman Sachs

Baird

Evercore ISI Group

Truist Securities

화요일 미국 주식 시장은 이날 상승세로 마감했다. 나스닥은 화요일에 1.4% 상승하여 19,912.53포인트에 도달했다. 다우도 1.2% 상승하여 43,089.02포인트에 거래되었으며, S&amp;P 500은 1.1% 상승하여 6,092.18포인트로 올랐다.
다음은 하루 동안 소매 투자자와 트레이더들의 주목을 받은 주요 주식이다.
빅베어AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>)
AI 솔루션 공급업체 빅베어AI 주가는 25.12% 급등하여 5.23달러로 마감했으며, 장중 최고가와 최저가는 각각 5.25달러와 4.23달러를 기록했다. 52주 최고가와 최저가는 각각 10.36달러와 1.16달러다. 회사는 최근 JFK, LAX, 시카고 오헤어 등 미국 및 국제 주요 공항에 <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46080056/bigbear-ai-bbai-stock-soars-21-whats-going-on" target="_blank" rel="noopener">생체 인식 승객 처리 소프트웨어를 도입</a>했다.
AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
반도체 거대 기업 AMD 주가는 6.83% 상승한 138.43달러로 마감했으며, 장중 최고가와 최저가는 각각 138.79달러와 132.93달러를 기록했다. 52주 최고가와 최저가는 각각 187.28달러와 76.48달러다. 회사는 최근 엔터프라이즈 디지털 전환을 가속화하기 위해 세계적인 기술 기업인 HCLTech와 <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46080942/why-amd-stock-is-soaring-tuesday" target="_blank" rel="noopener">전략적 제휴</a>를 발표했다.
퀀텀스케이프 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>)
퀀텀스케이프 주가는 2.00% 상승한 4.33달러로 마감했으며, 장중 최고가는 4.40달러, 최저가는 4.28달러를 기록했다. 52주 최고가는 9.52달러, 최저가는 3.40달러다. 이 회사는 최근 <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46084743/quantumscape-stock-is-surging-after-the-bell-whats-fueling-the-move">코브라( </a><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46084743/quantumscape-stock-is-surging-after-the-bell-whats-fueling-the-move" target="_blank" rel="noopener" data-google-interstitial="false">Cobra</a><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46084743/quantumscape-stock-is-surging-after-the-bell-whats-fueling-the-move" target="_blank" rel="noopener">) 분리막 공정이 기본 생산</a>에 진입했다고 발표하며, 생산 능력 확대에 중요한 이정표를 세웠다.
코인베이스 글로벌 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)
코인베이스 주가는 12.10% 상승한 344.82달러로 마감했으며, 장중 최고가는 348.97달러, 최저가는 311.90달러를 기록했다. 52주 최고가와 최저가는 각각 349.75달러와 142.58달러다. 회사의 주가는 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 가격의 <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46080547/whats-going-on-with-coinbase-shares-today-2" target="_blank" rel="noopener">반등</a>과 시장 전반의 리스크 심리가 개선된 데 따라 상승했다.
테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주가는 2.35% 하락한 340.47달러로 마감했으며, 장중 최고가는 356.26달러, 최저가는 340.44달러를 기록했다. 52주 최고가와 최저가는 각각 488.54달러와 182달러다. 테슬라의 <a href="https://www.benzinga.com/markets/tech/25/06/46069883/teslas-china-sales-slip-over-10-in-mid-june-after-strong-may-surge" target="_blank" rel="noopener">중국 판매량</a>은 5월에 꾸준한 성장을 보인 후 6월 셋째 주에 하락했다.
<figure class="wp-block-image size-full"></figure>
사진 출처: Billion Photos on Shutterstock.com
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

전 세계적으로 전기차(EV) 산업이 급성장함에 따라, 이는 전기차 배터리 기술 전문 기업인 퀀텀스케이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>)에 두 가지 이점을 제공한다. 첫째, 분명한 점은 차세대 차량이 많아지면 <a href="https://www.benzinga.com/money/best-electric-vehicle-stocks">고급 배터리에 대한 수요</a>가 높아진다는 것이다.
둘째, 에너지 효율적인 발전소는 <a href="https://www.benzinga.com/news/events/24/09/40798189/with-ev-sales-up-35-can-the-us-power-grid-keep-up-one-expert-weighs-in">전력망 인프라에 가해지는 추가 부담</a>을 완화하는 데 도움이 될 것이다. 따라서 QS 주식이 가끔 큰 폭으로 상승하는 것은 놀라운 일이 아니다.
그러나 문제는 이러한 긍정적인 모멘텀을 지속할 수 있는가 이다. 지난주 퀀텀스케이프 주식은 월요일 개장가와 금요일 종가 사이에 17.59% 상승했다. 불행히도 퀀텀스케이프가 공공 시장에 진입한 이후, 주식은 지속적인 상승 모멘텀을 보여주지 못했다.
퀀텀스케이프가 데뷔한 이후 주식 가치는 43% 이상 하락했다.
지난주의 큰 상승에도 불구하고, <a href="https://www.benzinga.com/insights/options/24/12/42691710/check-out-what-whales-are-doing-with-quantumscape">옵션 시장에서의 비정상적인 활동</a>는 회의적인 분위기가 고조되고 있음을 나타냈다. 12월 26일, 달러 거래량 기준으로 가장 큰 거래는 매도 콜 옵션에 대한 것이었으며, 특히 2025년 2월 21일 만기 $6 콜 옵션이었다. 기관 투자자들이 QS 주식에 대해 하락 베팅을 하고 있는 상황에서, 투기자는 낙관적으로 반대하는 이유가 필요할 것이다.
참고: <a href="https://www.benzinga.com/24/12/42680542/tesla-or-byd-which-ev-giant-will-sell-more-battery-electric-vehicles-in-q4">테슬라 또는 BYD &#8211; 4분기에 어떤 EV 거인이 더 많은 배터리 전기차를 판매할 것인가?</a>
<h2 class="wp-block-heading">역사적 추세는 QS 주식에 대한 회의론을 지지</h2>
퀀텀스케이프가 공공 시장에 데뷔한 이후 상황은 QS 주식의 긍정적인 접근을 지지하지 않는다. 주간 성과 기준으로 퀀텀스케이프는 단순히 부정적인 편향을 가지고 있다. 2020년 8월 이후 228주의 주가가 있었고, 그 중 96주만이 긍정적인 수익을 보였다. 이 통계를 기반으로 할 때, 주간 시작 시 수익이 부정적일 확률은 57.9%이다.
더욱이, 통계는 동적이고 조건적인 방식으로 접근할 때 악화된다. 앞서 언급했듯이, QS 주식은 지난주에 17.59% 급등했다. 2020년 8월 이후 퀀텀스케이프가 17.59% 이상 상승한 주는 19주였고, 이 중 4주 후에 QS가 긍정적이었던 경우는 7회에 불과했다.
상황을 바꿔 말하자면, 퀀텀스케이프 주식이 4주 후에 부정적일 확률은 63.2%이다 (12회 나누기 19주). 이 시점은 QS 옵션 체인이 2025년 1월 24일에 만기되는 날과 일치한다.
흥미롭게도, 12회의 부정적 사례들에서 평균 손실은 27.2%이다. 지난 금요일, 퀀텀스케이프 주식은 $5.95에 마감했다. 이 가격에서 27.2%를 차감하면 1월 24일까지 예상되는 하락 목표가 $4.33이 된다.
<h2 class="wp-block-heading">숫자 게임을 하다</h2>
QS 주식에 대한 회의론에도 불구하고, $4.70 수준에서 명확한 지지선이 존재한다. 이러한 현실 때문에 두 가지 접근 방식이 가능하며, 둘 다 <a href="https://help.benzinga.com/en/articles/6332560-bear-put-spread-options-trade">베어 풋 스프레드</a>라는 옵션 전략을 포함한다. 이 거래는 풋 옵션을 사고 동시에 낮은 행사가격의 풋 옵션을 매도하는 방식이다 (같은 옵션 체인 내에서). 숏 풋에서 받은 크레딧(credit)은 롱 풋에 대해 지불한 데빗(debit)의 일부를 상쇄한다.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" class="wp-image-711947" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30134512/QS-stock-12302024.jpg" sizes="(max-width: 1025px) 100vw, 1025px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30134512/QS-stock-12302024.jpg 1025w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30134512/QS-stock-12302024-300x174.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30134512/QS-stock-12302024-768x446.jpg 768w" alt="" width="1025" height="595" /></figure>
첫 번째 접근 방식은 트레이더가 $4.70 수준의 상승 지지를 존중한다고 가정한다. 따라서 $5.50/5.00 베어 풋 스프레드( $5.50 풋을 사고 $5 풋을 파는 것)가 매력적인 아이디어가 될 수 있다.
통계적으로 퀀텀스케이프 주식이 1월 24일까지 매도 가격인 $5로 하락할 가능성이 높다. 이 목표가 달성되면 (작성 시 기준) 최대 수익률은 61.29%이다.
두 번째 접근 방식은 더 공격적이다. 트레이더가 $4.70 지지선이 유지되지 않을 것이라고 믿는다면, $5.50/4.50 베어 풋 스프레드가 더 매력적일 수 있다. 퀀텀스케이프 주식이 $4.50 이하로 하락해야 최대 보상을 받을 수 있다. 그러나 현재 수익률은 매력적인 143.9%이다.
주가 움직임: 퀀텀스케이프의 주식은 월요일 7.73% 하락한 $5.49에 마감되었다.
지금 읽어보세요:
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/12/42726598/dow-jones-2024-scoreboard-top-5-winners-losers-and-how-amazon-nvidia-could-reshape-2025">다우존스 2024 점수판: 상위 5개 승자, 패자 &#8211; 그리고 아마존, 엔비디아가 2025년을 어떻게 재편할 수 있을까?</a></li>
</ul>
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

퀀텀스케이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>)는 수요일 2분기 재무 결과를 발표했다. <a href="https://www.benzinga.com/pressreleases/24/07/b39942492/quantumscape-reports-second-quarter-2024-business-and-financial-results">세부사항</a>은 다음과 같다.
주요 내용: 퀀텀스케이프는 GAAP 분기별 손실을 주당 25센트로 보고했는데, 이는 분석가의 합의 손실 추정치인 23센트를 8.7%나 하회한 것이다.
이 회사는 2분기 자본 지출이 1,890만 달러였으며, 주로 소량 QSE-5 프로토타입 생산을 위한 장비 구매와 코브라(Cobra) 프로세스 및 기타 장비 지원에 사용되었다고 보고했다. 이는 회사가 2025년 대량 QSE-5 프로토타입 생산을 준비하는 과정의 일환이다.
퀀텀스케이프는 9억 3,800만 달러의 유동성으로 2분기를 마감했다.
이 회사는 최근 파워코(PowerCo)와의 라이선스 계약을 통해 자본 효율적인 시장 진출 경로를 제공했으며 현재 현금 경로가 2028년까지 연장될 것으로 예상하고 있다고 밝혔다.
이 현금 흐름 예측 연장은 주로 공동 벤처에 대한 계획된 지출을 회피한 데 기인하며, 이는 공동 벤처 투자에 할당된 1억 3,400만 달러를 확보하게 했다. 또한, 만족스러운 기술 진행 상황에 따른 로열티 선지급, 협력 파트너로부터의 개발 자원 유입, 기존 운영의 자본 및 운영 효율성 개선도 주요 요인이다.
전망: 퀀텀스케이프는 조정 EBITDA 손실에 대한 2024년 연간 지침을 2억 5천만 달러에서 3억 달러 사이로 유지했으며 자본 지출 지침 범위인 7천만 달러에서 1억 2천만 달러의 하한선에 있을 것으로 예상한다.
관련 기사: <a href="https://www.benzinga.com/24/07/39940684/whats-going-on-with-meta-stock">메타 주식의 상황은?</a>
QS 주가 움직임: <a href="https://www.benzinga.com/24/07/39940684/whats-going-on-with-meta-stock">Benzinga Pro</a>에 따르면 퀀텀스케이프의 주식은 수요일 애프터마켓에서 6.30% 하락한 6.99달러를 기록했다. 이주식은 정규 거래 시간에 7.33% 하락한 7.46달러에 마감했다.
다음 소식: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39939280/whats-going-on-with-riot-platforms-stock">라이엇 플랫폼 주식은 무슨 일이?</a></li>
</ul>
이미지: QuantumScape Corporation 사진
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
<ol>
<li>퀀텀스케이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 <a href="https://www.benzinga.com//node/39727990" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">전고체 배터리 산업화</a> 계약을 체결했다고 발표한 후 64.34% 급등했다.</li>
<li>랜티우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)의 주가는 전문 <a href="https://www.benzinga.com//node/39717130" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">진단 방사성 의약품</a>에 대한 지불 개선을 위한 CMS 제안 이후 55.93% 급등했다.</li>
<li>선런(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>)의 주가는 37.59% 상승했다. 최근 CPI 데이터에 따라 더 넓은 산업 분야의 기업 주가가 상승했기 때문이다.</li>
<li>키메라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>)의 주가는 화농한선염과 아토피성 피부염에 대한 임상 2상을 확대해 <a href="https://www.benzinga.com//node/39675035" target="_blank" rel="noreferrer noopener">안전성 및 유효성</a>에 대한 중간 검토를 거쳐 중추적 연구로 보다 신속하게 진행하겠다는 의사를 밝힌 뒤 37.38% 상승했다.</li>
<li>아포지 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>)의 주식은 35.68% 급등했다.</li>
<li>조비 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>)은 회사가 <a href="https://www.benzinga.com//node/39733461" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">물을 유일한 부산물</a>로 사용하여 523마일을 수소 전기 항공 택시 시연차로 성공적으로 비행했다고 발표한 후 주가는 29.10% 상승했다.</li>
<li>크리네틱스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>)은 JP모건이 <a href="https://www.benzinga.com/quote/crnx/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 47달러에서 54달러로</a> 상향 조정한 후 주가는 21.18% 상승했다.</li>
<li>다인 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>)은 JP모건이 주식에 대해 비중확대 등급을 유지하고 <a href="https://www.benzinga.com/quote/DYN/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 39달러에서 43달러로</a> 높인 후 주가는 19.75% 상승했다.</li>
<li>서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식은 지난주 17.24% 급등했다.</li>
<li>플러그 파워(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>)의 주가는 <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39728268/inflation-slows-more-expected-to-3-in-june-heightens-expectations-for-rate-cuts-t" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">최근 소비자물가지수(CPI) 발표</a> 이후 전기차 관련주가 상승하면서 16.51% 상승했다. 미국 에너지부는 또한 폐쇄되었거나 위험에 처한 11개의 자동차 시설을 전기 자동차와 공급망 제조를 위해 전환하는 데 17억 달러를 투자한다고 발표했다.</li>
<li>샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>)의 주식은 15.56% 상승했다. 6월 중국의 수출이 증가한 것을 계기로 중국 관련 주식이 상승했다.</li>
</ol>
기타 읽어볼 만한 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/%eb%a6%ac%eb%b9%84%ec%95%88%ea%b3%bc-%eb%b0%94%ec%9d%b4%eb%91%90%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-11%ea%b0%9c%ec%9d%98-%eb%8c%80/" target="_blank" rel="noopener">리비안과 바이두는 지난주 최고 성과를 보인 11개의 대형주 주식 중 일부 (7월 7일-7월 13일)</a></li>
<li><a href="https://kr.benzinga.com/news/%eb%84%b7%ed%94%8c%eb%a6%ad%ec%8a%a4%ec%99%80-%eb%8d%b8%ed%83%80-%ed%95%ad%ea%b3%b5%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10/" target="_blank" rel="noopener">넷플릭스와 델타 항공은 지난주 최악의 성과를 보인 10대 대형주 중 일부 (7월 7일-7월 13일)</a></li>
</ul>
Photo Courtesy of QuantumScape
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

QuantumScape

뉴스

에 대한 최신 뉴스 QuantumScape (NYSE:QS) 주식

수요일, 6월 25, 2025

월요일, 12월 30, 2024

목요일, 7월 25, 2024

월요일, 7월 15, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌